• [email protected]
  • +971 507 888 742
Submit Manuscript
SciAlert
  • Home
  • Journals
  • Information
    • For Authors
    • For Referees
    • For Librarian
    • For Societies
  • Contact
  1. International Journal of Pharmacology
  2. Vol 8 (7), 2012
  3. 596-613
  • Online First
  • Current Issue
  • Previous Issues
  • More Information
    Aims and Scope Editorial Board Guide to Authors Article Processing Charges
    Submit a Manuscript

International Journal of Pharmacology

Year: 2012 | Volume: 8 | Issue: 7 | Page No.: 596-613
DOI: 10.3923/ijp.2012.596.613

Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail

Article Trend



Total views 135

Authors


A.H. Abdolghaffari

Country: Iran

S. Nikfar

Country: Iran

H.R. Rahimi

Country: Iran

M. Abdollahi

Country: Iran

Keywords


  • antibiotics
  • clinical trial
  • Crohn`s disease
  • Inflammatory bowel disease
  • ulcerative colitis
Review Article

A Comprehensive Review of Antibiotics in Clinical Trials for Inflammatory Bowel Disease

A.H. Abdolghaffari, S. Nikfar, H.R. Rahimi and M. Abdollahi
Although, positive role of special bacteria in induction of Inflammatory Bowel Disease (IBD) including Ulcerative Colitis (UC) and Crohn’s Disease (CD) have been demonstrated in several studies but the consensus on etiology of IBD and beneficial effect of antibiotics has not been reached yet. And, also, no well-designed clinical trials in this regard have been done yet. This review focuses on various clinical trials which have been done in according to beneficial use of antibiotics in UC and CD from 1978 to date. For this purpose, all electronic databases such as PubMed, Scopus, Google Scholar and Cochrane library were searched. The results of clinical trials suggested that metronidazole, ciprofloxacin or the combinations of these antibiotics are effective in CD. However, ciprofloxacin is the first choice, because it has good coverage on gram negative and anaerobic bacterium which plays an important role in CD. However, there is a controversy on the use of antibiotics in UC and the efficacy of them in long-term treatment of UC is still in doubt. Various antibiotics such as anti-tuberculosis, macrolides (clarithromycin), fluoroquinolones, 5-nitroimidazoles, rifaximin, rifamycin derivatives (rifampin), aminoglycosides (tobramycin), rifabutin, clofazimine, tetracyclines (tetracycline and doxycycline) and vancomycin have been under attention of researchers in the recent years. Furthermore, other antibiotics with lower cost and adverse effects, effectiveness and availability are the third generation of cephalosporins and gentamicin and also penicillin or clindamycin that should be evaluated in future studies.
PDF Fulltext XML References Citation

How to cite this article

A.H. Abdolghaffari, S. Nikfar, H.R. Rahimi and M. Abdollahi, 2012. A Comprehensive Review of Antibiotics in Clinical Trials for Inflammatory Bowel Disease. International Journal of Pharmacology, 8: 596-613.

DOI: 10.3923/ijp.2012.596.613

URL: https://scialert.net/abstract/?doi=ijp.2012.596.613

Related Articles

Comparison of the Efficacy and Tolerability of Herbal Medicines with 5-aminosalisylates in Inflammatory Bowel Disease: A Meta-analysis of Placebo Controlled Clinical Trials Involving 812 Patients
A Review and Meta-analysis of the Efficacy of Antibiotics and Probiotics in Management of Pouchitis

Leave a Comment


Your email address will not be published. Required fields are marked *

Useful Links

  • Journals
  • For Authors
  • For Referees
  • For Librarian
  • For Socities

Contact Us

Office Number 1128,
Tamani Arts Building,
Business Bay,
Deira, Dubai, UAE

Phone: +971 507 888 742
Email: [email protected]

About Science Alert

Science Alert is a technology platform and service provider for scholarly publishers, helping them to publish and distribute their content online. We provide a range of services, including hosting, design, and digital marketing, as well as analytics and other tools to help publishers understand their audience and optimize their content. Science Alert works with a wide variety of publishers, including academic societies, universities, and commercial publishers.

Follow Us
© Copyright Science Alert. All Rights Reserved